Skip to content
Preprint · CC-BY via OpenAlex

Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial

Michael J. Corley, Varun B. Dwaraka, Alina P.S. Pang, Danielle E. Labbato, Ryan S. Smith, Allison Ross Eckard, Grace A. McComsey

medRxiv · 2025 · ▲ 4 citations

Abstract

Semaglutide is a once-weekly GLP-1 receptor agonist that has been proposed as a gerotherapeutic, yet no data exist on its effects on epigenetic aging. We therefore conducted a post-hoc epigenetic analysis of a 32-week, double-blind, placebo-controlled phase 2b trial in adults with HIV-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). Paired peripheral-blood methylomes were profiled to evaluate semaglutide's impact across multiple generations of DNA-methylation clocks. After adjustment for sex, BMI, hsCRP, and sCD163, semaglutide significantly decreased epigenetic aging: PCGrimAge (-3.1 years, P = 0.007), GrimAge V1 (-1.4 years, P = 0.02), GrimAge V2 (-2.3 years, P = 0.009), PhenoAge (-4.9 years, P = 0.004), and DunedinPACE (-0.09 units, ≈9 % slower pace, P = 0.01). Semaglutide also lowered the multi-omic OMICmAge clock (-2.2 years, P = 0.009) and the transposable element-focused RetroAge clock (-2.2 years, P = 0.030). Eleven organ-system clocks showed concordant decreased with semaglutide, most prominently inflammation, brain and heart, whereas an Intrinsic Capacity epigenetic clock(definition) was unchanged (P = 0.31). These findings provide, to our knowledge, the first clinical-trial evidence that semaglutide modulates validated epigenetic biomarkers of aging, justifying further evaluation of GLP-1 receptor agonists for health-span extension.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1101/2025.07.09.25331038
Canonical
link ↗
Fetched
2026-10-16 MST

Cite this

APA
Corley, M.J., Dwaraka, V.B., Pang, A.P., Labbato, D.E., Smith, R.S., Eckard, A.R., &amp; McComsey, G.A. (2025). Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial. <em>medRxiv</em>. https://doi.org/10.1101/2025.07.09.25331038
Vancouver
Corley MJ, Dwaraka VB, Pang AP, Labbato DE, Smith RS, Eckard AR, et al. Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial. medRxiv. 2025. doi:10.1101/2025.07.09.25331038.
BibTeX
@unpublished{michael2025Semagl, title = {Semaglutide Slows Epigenetic Aging in People with HIV-associated lipohypertrophy: Evidence from a Randomized Controlled Trial}, author = {Michael J. Corley and Varun B. Dwaraka and Alina P.S. Pang and Danielle E. Labbato and Ryan S. Smith and Allison Ross Eckard and Grace A. McComsey}, journal = {medRxiv}, year = {2025}, doi = {10.1101/2025.07.09.25331038}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings